Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

• I. Blancas ^[3] ; E. Aguirre ^[4] ; S. Morales ^[4] ; M. L. Gonzálvez ^[5] ; S. Servitja ^[1] ; N. Díaz ^[6] ; S. del Barco ^[2] ; A. Barnadas ^[7] ; M. Margelí ^[2] ; I. García Carbonero ^[8] ; A. Llombart ^[9]
  1. [1] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  2. [2] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  3. [3] University Hospital San Cecilio, Granada
  4. [4] University Hospital Arnau de Vilanova, Lleida
  5. [5] University Hospital Arrixaca, Murcia
  6. [6] University Hospital San Juan de Alicante
  7. [7] University Hospital Sant Pau, Barcelona
  8. [8] Virgen de La Salud Hospital, Toledo
  9. [9] Arnau de Vilanova Hospital, Valencia

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 4, 2019, págs. 459-466
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To evaluate the efficacy and safety of oral weekly vinorelbine 60 mg/m2 for metastatic breast cancer (MBC) in patients previously treated with anthracyclines or taxanes in routine clinical practice.

    Materials and methods Fifty-five patients were enrolled in a prospective multicentre study conducted in Spain. Women ≥ 18 years of age with locally advanced breast cancer who were not candidates for surgical treatment with a radical intention or patients with stage IV disease, and who had received a prior taxane or anthracycline regimen were eligible for participation.

    Results Median age was 67 years. Median progression-free survival was 3.7 months (95% CI 2.5–4.9), median overall survival 10 months (95% CI 6.6–13.5), and overall response rate and clinical benefit rate were 29.1% and 49.1%, respectively. Main grade 3 and 4 toxicities were neutropenia 9.1%, febrile neutropenia 3.6% and constipation 3.6%. In total, 86% of the patients received complete treatment without delays or dose reduction. Moreover, HER2-positive patients who received oral vinorelbine concomitantly with trastuzumab showed better response (complete response: HER2-positive 14.3% vs. HER2-negative 0%; partial response: HER2-positive 42.9% vs. HER2-negative 25.6%; p = 0.008), better disease control rate (HER2-positive 100% vs. HER2-negative 46.2%; p = 0.011), and better values for the remaining analysed variables than HER2-negative patients.

    Conclusion Our study provides real-world data on the use of oral weekly vinorelbine, which proves an effective and well-tolerated regimen for MBC patients previously treated with taxanes or anthracyclines. Patients with HER2-positive disease could also benefit from this treatment in combination with trastuzumab.